{
  "trial_id": "NCT00188240",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "serologic evidence of chronic hepatitis C infection by an anti-HCV antibody test",
      "label": "met"
    },
    {
      "criterion": "detectable serum HCV-RNA",
      "label": "met"
    },
    {
      "criterion": "negative urine or blood pregnancy test (for women of childbearing potential)",
      "label": "met"
    },
    {
      "criterion": "all fertile males and females receiving Copegus must be using two forms of effective contraception during treatment and during the 6 months after treatment end",
      "label": "unknown"
    },
    {
      "criterion": "all patients should have insulin resistance (>2.1) determined by the homeostasis model",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "women with ongoing pregnancy or breast feeding",
      "label": "not_met"
    },
    {
      "criterion": "therapy with any systemic anti-neoplastic or immunomodulatory treatment (including supraphysiologic doses of steroids and radiation) < 6 months prior to the first dose of study drug",
      "label": "unknown"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "27",
    "trial_id": "NCT00188240",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}